Streetbeat News

Regulatory

PFE

RLAY

Relay Therapeutics shared promising interim data for its breast cancer treatment, RLY-2608, showing significant progression-free survival in heavily pretreated patients. The company is advancing towards a pivotal trial and plans to seek a global commercialization partner for another drug, lirafugratinib. Relay's stock rose significantly following the news.

Portfolio Pulse from Vandana Singh

September 09, 2024 | 3:30 pm

SPY

The New York Federal Reserve reported that consumer inflation expectations for the next year remain unchanged at 3.0% for August. This stability in expectations may influence market sentiment and investor behavior.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 3:02 pm

C

Citi's CFO highlights the bank's focus on data quality and regulatory initiatives. The bank is reviewing resources for regulatory projects that are delayed. Despite a 4% YoY decline in Q3 markets revenue, investment banking fees are up 20% YoY, and debt capital markets activity remains strong.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 2:55 pm

RZLT

The FDA has lifted partial clinical holds on Rezolute's RZ358, a treatment for congenital hyperinsulinism, allowing the company to proceed with its Phase 3 study in the U.S. The study aims to include U.S. participants by early 2025, with results expected in the second half of 2025. Rezolute's stock rose 14.5% following the announcement.

Portfolio Pulse from Vandana Singh

September 09, 2024 | 2:42 pm

RTX

RTX Corp.'s $7.6 billion GPS-tracking network project faces further delays and issues, as reported by the GAO. This could impact its acceptance by the US Space Force.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 2:39 pm

INBS

Intelligent Bio Solutions Inc. (NASDAQ:INBS) saw a significant stock price increase on Monday, driven by a 64% year-over-year revenue growth in Q4 2024 and a 148% increase in fiscal year sales. The company is progressing with its FDA 510(k) submission and has expanded its customer base, contributing to the positive market response.

Portfolio Pulse from Vandana Singh

September 09, 2024 | 2:24 pm

BIIB

ESALY

Biogen's Alzheimer's drug Leqembi, developed with Eisai, offers hope for early-stage Alzheimer's patients by slowing cognitive decline. Despite logistical challenges and side effects, sales have grown since its approval. Biogen is working on making the treatment more accessible.

Portfolio Pulse from Vandana Singh

September 09, 2024 | 2:12 pm

STLA

The U.S. is investigating reports that 2021-2023 Jeep Wrangler and Gladiator vehicles may catch fire after the engines are turned off. This investigation could impact Stellantis, the parent company of Jeep.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 1:47 pm

HALB

Halberd Corp. has issued a letter to shareholders discussing the evolving PTSD market and their innovative solutions, including the WatchDawg and LDX medication combination. The company highlights advancements in PTSD treatment, government support, and the integration of mental health services. They emphasize their wearable technology for real-time health monitoring and the potential for franchising their WatchDawg business model. Halberd is pursuing FDA Fast Track designation for their LDX solution and exploring Breakthrough Therapy designation.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 1:33 pm

FANH

WDH

Waterdrop Inc. (NYSE:WDH) reported a slight revenue decline in Q2 but a significant profit increase due to cost control. The company reaffirmed its annual growth forecast and announced a special dividend. Challenges include regulatory changes affecting insurance brokers and a decline in revenue from its clinical trial business. Waterdrop's shares rose 5.7% following the announcement.

Portfolio Pulse from The Bamboo Works

September 09, 2024 | 1:25 pm